Abstract
In the past 3 decades introduction of prenatal steroid treatment, postnatal surfactant therapy and assisted ventilation have lead directly to improved neonatal outcomes [1]. Improved survival is directly related to more effective prevention or treatment of respiratory distress syndrome (RDS), which prior to the 1990s had a high mortality. Following unsuccessful clinical trials with nebulized synthetic surfactants, comprised of phospholipids without surfactant proteins, in the 1960s [2] a number of randomized controlled trials in the 1980s demonstrated benefits of surfactants instilled directly into the lungs of preterm infants [3–5]. These surfactants were of 2 main types: natural (derived from animal lungs or human amniotic fluid) [3] containing surfactant proteins-B and C (SP-B and SP-C) and synthetic [4, 5] (containing phospholipids and other agents to facilitate spreading and adsorption). Both types of surfactant given, either prophylactically (in the delivery room within 15 minutes of birth) [3, 4] or for treatment of RDS [5], increased neonatal survival and reduced pulmonary air leaks such as pneumothoraces and pulmonary interstitial emphysema.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sweet DG, Halliday HL (2009) The use of surfactants in 2009. Arch Dis Child Educ Pract Ed 94: 78–83
Halliday HL (2008) Surfactants: past, present and future. J Perinatol 28: S47–S56
Soll RF (2000) Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2:CD000511
Soll RF (2000) Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2:CD001079
Soll RF (2000) Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2: CD001149
Sweet DG, Carnielli V, Greisen G et al (2007) European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants - 2010 update. Neonatology 97: 402–417
Engle WA, American Academy of Pediatrics Committee on Fetus and Newborn (2008) Surfactant-replacement therapy for respiratory distress syndrome in the preterm and term neonate. Pediatrics 121: 419–432
Fetus and Newborn Committee, Canadian Paediatric Society (2005) Recommendations for neonatal surfactant therapy. J Paediatr Child Health 10: 109–116
Working Group of the British Association of Perinatal Medicine (1998) Guidelines for good practice in management of neonatal respiratory distress syndrome. http://www.bapm.org/media/documents/ publications/rds.pdf (accessed on 12 January 2011)
Avery ME, Mead J (1959) Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 97: 517–523
Halliday HL (2003) Respiratory distress syndrome. In: Greenough A, Milner AD (eds) Neonatal respiratory disorders, 2 edn. Arnold, London, pp 247–271
Soll RF, Blanco F (2001) Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2:CD000144
Soll RF, Morley CJ (2001) Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2:CD000510
Jobe AH, Michell BR, Gunkel JH (1993) Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol 168: 508–513
Yost CC, Soll RF (2000) Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2:CD001456
Egberts J, Brand R, Walti H et al (1997) Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of surfactant. Pediatrics 100: e4
Walti H, Paris-Llado J, Egberts J et al (2002) Prophylactic administration of porcine-derived lung surfactant is a significant factor in reducing the odds for peri-intraventricular haemorrhage in premature infants. Biol Neonate 81: 182–187
Kendig JW, Ryan RM, Sinkin RA et al (1998) Comparison of two strategies for surfactant prophylaxis in very premature infants: a multicenter randomized trial. Pediatrics 101: 1006–1012
Kattwinkel J, Bloom BT, Delmore P et al (1993) Prophylactic administration of calf lung surfactant is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks’ gestation. Pediatrics 92: 90–98
Morley CJ (1991) Surfactant treatment of premature babies: a review of clinical trials. Arch Dis Child 66: 445–450
Halliday HL, Robertson B (1994) Surfactant replacement. In: Hanson MA, Spencer JAD, Rodeck CH, Walters D (eds) Fetus and Neonate: Physiology and Clinical Applications, Vol 2, Breathing. Cambridge University Press, Cambridge, pp 265–302
Konishi M, Fujiwara T, Naito T et al (1988) Surfactant replacement therapy in neonatal respiratory distress syndrome. A multicenter randomised clinical trial: comparison of high versus low-dose of Surfactant TA. Eur J Pediatr 147: 20–25
Gortner L, Pohlandt F, Bartmann P et al (1994) High-dose versus low-dose bovine surfactant treatment in very premature infants. Acta Paediatr 83: 135–141
Halliday HL, Tarnow-Mordi WO, Corcoran JD et al (1993) Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child 69: 276–280
Ramanathan R, Rasmussen MR, Gerstmann DR et al (2004) A randomised, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant ( Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 21: 109–119
Hallman M (1989) Recycling of surfactant: a review of human amniotic fluid as a source of surfactant for treatment of respiratory distress syndrome. Rev Perinat Med 6: 197–226
Ueda T, Ikegami M, Rider ED et al (1994) Distribution of surfactant and ventilation in surfactant-treated preterm lambs. J Appl Physiol 76: 45–55
Zola EM, Gunkel JH, Chan RK et al (1993) Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome. J Pediatr 122: 453–459
Valls-i-Soler A, Fernandez-Ruanova B, Lopez-Heredia J et al (1998) A randomised comparison of surfactant dosing via a dual-lumen endotracheal tube in respiratory distress syndrome. Pediatrics 101: E4
Vento M, Cheung P-Y, Aguar M (2009) The first golden minutes of the extremely-low-gestational-age neonate: a gentle approach. Neonatology 95: 286–298
Bohlin K, Jonsson B, Gustafsson AS et al (2008) Continuous positive airway pressure and surfactant. Neonatology 93: 309–315
Stevens TP, Harrington EW, Blennow M et al (2007) Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 4:CD003063
Berggren P, Liljedahl M, Winbladh B et al (2000) Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr 89: 460–464
Kribs A, Vierzig A, Hunseler C et al (2008) Early surfactant in spontaneously breathing with nCPAP in ELBW infants–a single center four year experience. Acta Paediatr 97: 293–298
Kattwinkel J, Robinson M, Bloom BT et al (2004) Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. J Perinatol 24: 360–365
Trevisanuto D, Grazzina N, Ferrasse P et al (2005) Laryngeal mask airway used as a delivery conduit for the administration of surfactant to preterm infants with respiratory distress syndrome. Biol Neonate 87: 217–220
Dunn MS, Shennan AT, Possmayer F (1990) Single versus multiple- dose surfactant replacement therapy in neonates of 30 to 36 weeks’ gestation with respiratory distress syndrome. Pediatrics 86: 567–571
Speer CP, Robertson B, Curstedt T et al (1992) Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 89: 13–20
Soll RF (1999) Multiple versus single dose natural surfactant extract for severe neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2:CD0000141
Kattwinkel J, Bloom BT, Delmore P et al (2000) High- versus lowthreshold surfactant retreatment for neonatal respiratory distress syndrome. Pediatrics 106: 282–288
Halliday HL (2006) Recent clinical trials of surfactant treatment for neonates. Biol Neonate 89: 323–329
Moya F, Gadzinowski J, Bancalari E et al (2005) A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome in very preterm infants. Pediatrics 115: 1018–1029
Inha S, Lacaze-Masmoneil T, Valls-i-Soler A et al (2005) A randomized, controlled trial of lucinactant versus poractant alfa in very premature infants at high risk for respiratory distress syndrome. Pediatrics 115: 1030–1038
Curstedt T, Johansson J (2006) New synthetic surfactants–how and when?. Biol Neonate 89: 336–339
Bloom BT, Clark RH (2005) Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics 116: 392–399
Halliday HL (2005) History of surfactant from 1980. Biol Neonate 87: 317–322
Kattwinkel J (2005) Synthetic surfactants: the search goes on. Pediatrics 115: 1075–1076
Pfister RH, Soll RF, Wiswell T (2007) Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev 4:CD006069
Stevens TP, Sinkin RA (2007) Surfactant replacement therapy. Chest 131: 1577–1582
Ramanathan R (2009) Choosing a right surfactant for respiratory distress syndrome treatment. Neonatology 95: 1–5
Roberts D, Dalziel S (2006) Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 3:CD004454
Jobe AH, Mitchell BR, Gunkel JH (1993) Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol 168: 508–513
Dani C, Bertini G, Pezzati M et al (2004) Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants 30 weeks’ gestation. Pediatrics 113: e560–563
Sandri F, Plavka R, Simeoni U et al (2008) The CURPAP study: an international randomized controlled trial to evaluate the efficacy of combining prophylactic surfactant and early nasal continuous positive airway pressure in very preterm infants. Neonatology 94: 60–62
Verder H, Albertsen P, Ebbesen F et al (1999) Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks’ gestation. Pediatrics 103: e24
Morley CJ, Davis PG, Doyle LW et al (2008) Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 358: 700–708
Schmidt B, Roberts R, Davis P et al (2006) Caffeine therapy for apnea of prematurity. N Engl J Med 354: 2112–2121
Schmidt B, Roberts RS, Davis P et al (2007) Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 357: 1893–1902
El Shahed AI, Dargaville P, Ohlsson A et al (2007) Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database Syst Rev 3:CD002054
Dargaville PA, Copnell B, Tingay DG et al (2008) Refining the method of therapeutic lung lavage in meconium aspiration syndrome. Neonatology 94: 160–163
Lotze A, Mitchell BR, Bulas DJ et al (1998) Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. J Pediatr 132: 40–47
Herting E, Gefeller O, Land M et al (2000) Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics 106: 957–964
Halliday HL, Speer CP (1995) Strategies for surfactant therapy in established neonatal respiratory distress syndrome. In: Robertson B, Taeusch HW (eds) Surfactant Therapy for Lung Disease. Marcell Dekker, New York, pp 443–459
Aziz A, Ohlsson A (2008) Surfactant for pulmonary hemorrhage in neonates. Cochrane Database Syst Rev 2:CD005254
Pandit PB, Dunn MS, Kelly EN et al (1995) Surfactant replacement in neonates with early chronic lung disease. Pediatrics 95: 851–854
Yeh TF, Lin HC, Chang CH et al (2008) Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics 121:e1310– e1318
Finer NN (2004) Surfactant use for neonatal lung injury: beyond respiratory distress syndrome. Paediatr Respir Rev 5 (suppl A): S289–S297
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Italia
About this chapter
Cite this chapter
Halliday, H.L. (2012). Lung Diseases: Surfactant Replacement Therapy. In: Buonocore, G., Bracci, R., Weindling, M. (eds) Neonatology. Springer, Milano. https://doi.org/10.1007/978-88-470-1405-3_70
Download citation
DOI: https://doi.org/10.1007/978-88-470-1405-3_70
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1404-6
Online ISBN: 978-88-470-1405-3
eBook Packages: MedicineMedicine (R0)